Open AccessCOST-EFFECTIVENESS AND COST-UTILITY OF GENOTHERAPEUTIC DRUG NEOVASCULGEN IN TREATMENT OF CHRONIC LOWER LIMB ISCHEMIA
Author(s) -
S. L. Plavinsky,
П. И. Шабалкин
Publication year - 2017
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2017-14-132-135
Subject(s) - medicine , drug , drug treatment , lower limb , clinical trial , cost–utility analysis , cost effectiveness , physical therapy , intensive care medicine , surgery , pharmacology , risk analysis (engineering)
Pl-VEGF165 (Neovasculgen) is a new genotherapeutic drug for treatment of chronic lower limb ischemia. It is registered in Russia and underwent effectiveness assessment in clinical trial. Objective of this study is to report results of the economical modeling study to compare long-term effectiveness and costs of the treatment. The comparison show that the treatment with this drug allows to decrease number of amputations by 6.5 fold and increase quality adjusted length of life by 2.6 QALYs. Summary costs were lower with new drug by 574 thousand rubles with lifelong modeling and by 353 thousand rubles in first 5 years.